Abstract
Tumour necrosis factor-alpha (TNF alpha) is thought to have a central role in the pathogenesis of Crohn's disease. We tested the hypothesis that CDP571, a genetically engineered human antibody to TNF alpha, is effective in modifying disease activity in patients with moderately active Crohn's disease.
Original language | English |
---|---|
Pages (from-to) | 521-524 |
Number of pages | 4 |
Journal | The Lancet |
Volume | 349 |
Issue number | 9051 |
DOIs | |
Publication status | Published - 22 Feb 1997 |
Keywords
- Adolescent
- Adult
- Aged
- Antibodies
- C-Reactive Protein
- Crohn Disease
- Double-Blind Method
- Glycoproteins
- Humans
- Middle Aged
- Placebos
- Remission Induction
- Tumor Necrosis Factor-alpha